Theravance Biopharma Expects Non-GAAP Loss In H1 Of 2024 And Approach Non-GAAP Breakeven In H2 Of 2024; Limited Cash Burn Expected In 2024
Theravance Biopharma Expects Non-GAAP Loss In H1 Of 2024 And Approach Non-GAAP Breakeven In H2 Of 2024; Limited Cash Burn Expected In 2024
Theravance Biopharma预计,2024年上半年将出现非公认会计准则亏损,并在2024年下半年接近非公认会计准则盈亏平衡;预计2024年现金消耗有限
Theravance Biopharma Expects Non-GAAP Loss In H1 Of 2024 And Approach Non-GAAP Breakeven In H2 Of 2024; Limited Cash Burn Expected In 2024
Theravance Biopharma预计,2024年上半年将出现非公认会计准则亏损,并在2024年下半年接近非公认会计准则盈亏平衡;预计2024年现金消耗有限